Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC.RXRX · Entity 1008 | President and COO | November 15, 2024 | November 19, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RECURSION PHARMACEUTICALS, INC.
Report date November 15, 2024 · Filed November 19, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 506,852 |
Reported balance
After 2024-11-15 transaction · row 1
1 source rowRow 1 · 2024-11-15 · Tax withholding · Disposed 14,286 · Balance 506,852 F1: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.06 · Expires 2028-07-22 | Direct | 452,000 |
Reported balance
Holding disclosure · report date 2024-11-15 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 452,000 F2: Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.55 · Expires 2033-02-01 | Direct | 434,122 |
Reported balance
Holding disclosure · report date 2024-11-15 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 434,122 F3: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.40 · Expires 2032-02-04 | Direct | 159,226 |
Reported balance
Holding disclosure · report date 2024-11-15 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 159,226 F4: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.40 · Expires 2032-02-04 | Direct | 4,784 |
Reported balance
Holding disclosure · report date 2024-11-15 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 4,784 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.48 · Expires 2030-12-30 | Direct | 150,000 |
Reported balance
Holding disclosure · report date 2024-11-15 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 150,000 F5: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after December 31, 2020, or the Monthly Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Monthly Vesting Commencement Date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.09 · Expires 2034-02-09 | Direct | 447,917 |
Reported balance
Holding disclosure · report date 2024-11-15 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 447,917 F6: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
F2: Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date.
F3: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
F4: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
F5: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after December 31, 2020, or the Monthly Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Monthly Vesting Commencement Date.
F6: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 15, 2024 Filed Nov 19, 2024 23:26 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 14,286 | $6.18 | $88,216.05 |
DisclosureSEC source: 0001601830-24-000213 · wk-form4_1732058770.xml · nonDerivative · entry 1 Marriott Tina · CIK 0001856414 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 506,852 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| October 24, 2024 Filed Oct 28, 2024 21:25 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001601830-24-000181 · wk-form4_1730150699.xml · derivative · entry 3 Marriott Tina · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 452,000 Underlying: Class A Common Stock · 6,000 shares Expires 2028-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2024. F3 · derivative.exercise_date: Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date. Read SEC document |
| October 24, 2024 Filed Oct 28, 2024 21:25 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 6,000 | $6.31 | $37,854.60 |
DisclosureSEC source: 0001601830-24-000181 · wk-form4_1730150699.xml · nonDerivative · entry 2 Marriott Tina · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 521,138 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $6.22 to $6.43 The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| October 24, 2024 Filed Oct 28, 2024 21:25 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 6,000 | $1.06 | $6,360.00 |
DisclosureSEC source: 0001601830-24-000181 · wk-form4_1730150699.xml · nonDerivative · entry 1 Marriott Tina · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 527,138 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2024. Read SEC document |
| September 26, 2024 Filed Sep 30, 2024 22:15 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 0 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001601830-24-000161 · wk-form4_1727734527.xml · derivative · entry 3 Marriott Tina · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 458,000 Underlying: Class A Common Stock · 6,000 shares Expires 2028-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2024. F3 · derivative.exercise_date: Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date. Read SEC document |
| September 26, 2024 Filed Sep 30, 2024 22:15 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 6,000 | $7.00 | $42,004.80 |
DisclosureSEC source: 0001601830-24-000161 · wk-form4_1727734527.xml · nonDerivative · entry 2 Marriott Tina · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 521,138 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $6.84 to $7.16 The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 26, 2024 Filed Sep 30, 2024 22:15 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 6,000 | $1.06 | $6,360.00 |
DisclosureSEC source: 0001601830-24-000161 · wk-form4_1727734527.xml · nonDerivative · entry 1 Marriott Tina · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 527,138 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2024. Read SEC document |
| August 29, 2024 Filed Sep 3, 2024 20:48 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001601830-24-000150 · wk-form4_1725396515.xml · derivative · entry 3 Marriott Tina · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 464,000 Underlying: Class A Common Stock · 6,000 shares Expires 2028-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2024. F3 · derivative.exercise_date: Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date. Read SEC document |
| August 29, 2024 Filed Sep 3, 2024 20:48 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 6,000 | $7.56 | $45,376.20 |
DisclosureSEC source: 0001601830-24-000150 · wk-form4_1725396515.xml · nonDerivative · entry 2 Marriott Tina · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 521,138 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $7.34 to $7.77 The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 29, 2024 Filed Sep 3, 2024 20:48 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 6,000 | $1.06 | $6,360.00 |
DisclosureSEC source: 0001601830-24-000150 · wk-form4_1725396515.xml · nonDerivative · entry 1 Marriott Tina · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 527,138 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2024. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 23:09 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 14,319 | $6.69 | $95,794.11 |
DisclosureSEC source: 0001601830-24-000128 · wk-form4_1724108986.xml · nonDerivative · entry 1 Marriott Tina · CIK 0001856414 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 521,138 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| July 25, 2024 Filed Jul 29, 2024 22:16 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001601830-24-000105 · wk-form4_1722291370.xml · derivative · entry 3 Marriott Tina · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 470,000 Underlying: Class A Common Stock · 6,000 shares Expires 2028-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2024. F3 · derivative.exercise_date: Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date. Read SEC document |
| July 25, 2024 Filed Jul 29, 2024 22:16 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 6,000 | $8.13 | $48,809.40 |
DisclosureSEC source: 0001601830-24-000105 · wk-form4_1722291370.xml · nonDerivative · entry 2 Marriott Tina · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 535,457 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $7.73 to $8.5. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 25, 2024 Filed Jul 29, 2024 22:16 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 6,000 | $1.06 | $6,360.00 |
DisclosureSEC source: 0001601830-24-000105 · wk-form4_1722291370.xml · nonDerivative · entry 1 Marriott Tina · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 541,457 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2024. Read SEC document |
| June 27, 2024 Filed Jun 28, 2024 21:14 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001601830-24-000095 · wk-form4_1719609240.xml · derivative · entry 3 Marriott Tina · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 476,000 Underlying: Class A Common Stock · 6,000 shares Expires 2028-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2024. F3 · derivative.exercise_date: Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date. Read SEC document |
| June 27, 2024 Filed Jun 28, 2024 21:14 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 6,000 | $7.22 | $43,290.00 |
DisclosureSEC source: 0001601830-24-000095 · wk-form4_1719609240.xml · nonDerivative · entry 2 Marriott Tina · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 535,457 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $6.91 to $7.575. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 27, 2024 Filed Jun 28, 2024 21:14 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 6,000 | $1.06 | $6,360.00 |
DisclosureSEC source: 0001601830-24-000095 · wk-form4_1719609240.xml · nonDerivative · entry 1 Marriott Tina · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 541,457 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2024. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 22:31 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 0 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001601830-24-000068 · wk-form4_1717453891.xml · derivative · entry 3 Marriott Tina · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 482,000 Underlying: Class A Common Stock · 3,000 shares Expires 2028-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023. F4 · derivative.exercise_date: Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 22:31 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 3,000 | $8.78 | $26,325.00 |
DisclosureSEC source: 0001601830-24-000068 · wk-form4_1717453891.xml · nonDerivative · entry 2 Marriott Tina · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 535,457 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $8.65 to $8.88. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 22:31 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 3,000 | $1.06 | $3,180.00 |
DisclosureSEC source: 0001601830-24-000068 · wk-form4_1717453891.xml · nonDerivative · entry 1 Marriott Tina · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 538,457 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023. F2 · balance_after: Includes 2,224 shares purchased pursuant to the Issuer's Employee Stock Purchase Plan on May 20, 2024. Read SEC document |
| May 15, 2024 Filed May 17, 2024 23:12 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 9,998 | $10.01 | $100,079.98 |
DisclosureSEC source: 0001601830-24-000059 · wk-form4_1715987524.xml · nonDerivative · entry 1 Marriott Tina · CIK 0001856414 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 533,233 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| April 25, 2024 Filed Apr 29, 2024 22:41 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001601830-24-000045 · wk-form4_1714430473.xml · derivative · entry 3 Marriott Tina · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 485,000 Underlying: Class A Common Stock · 3,000 shares Expires 2028-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023. F4 · derivative.exercise_date: Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date. Read SEC document |
| April 25, 2024 Filed Apr 29, 2024 22:41 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 3,000 | $7.67 | $23,020.50 |
DisclosureSEC source: 0001601830-24-000045 · wk-form4_1714430473.xml · nonDerivative · entry 2 Marriott Tina · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 543,231 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $7.5 to $7.86. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 25, 2024 Filed Apr 29, 2024 22:41 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 3,000 | $1.06 | $3,180.00 |
DisclosureSEC source: 0001601830-24-000045 · wk-form4_1714430473.xml · nonDerivative · entry 1 Marriott Tina · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 546,231 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023. F2 · balance_after: Since the Reporting Person's last ownership report, she has transferred 96,751 shares of RXRX Class A Common Stock to her former spouse pursuant to a domestic relations order. The Reporting Person no longer reports as beneficially owned any securities owned by her former spouse. Read SEC document |
| March 21, 2024 Filed Mar 25, 2024 22:39 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001601830-24-000025 · wk-form4_1711406339.xml · derivative · entry 4 Marriott Tina · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 488,000 Underlying: Class A Common Stock · 8,000 shares Expires 2028-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023. F4 · derivative.exercise_date: Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date. Read SEC document |
| March 21, 2024 Filed Mar 25, 2024 22:39 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 610 | $11.34 | $6,915.02 |
DisclosureSEC source: 0001601830-24-000025 · wk-form4_1711406339.xml · nonDerivative · entry 3 Marriott Tina · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 639,982 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $11.28 to $11.40. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 21, 2024 Filed Mar 25, 2024 22:39 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 7,390 | $10.70 | $79,064.87 |
DisclosureSEC source: 0001601830-24-000025 · wk-form4_1711406339.xml · nonDerivative · entry 2 Marriott Tina · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 640,592 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $10.28 to $11.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 21, 2024 Filed Mar 25, 2024 22:39 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 8,000 | $1.06 | $8,480.00 |
DisclosureSEC source: 0001601830-24-000025 · wk-form4_1711406339.xml · nonDerivative · entry 1 Marriott Tina · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 647,982 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023. Read SEC document |
| February 22, 2024 Filed Feb 24, 2024 00:22 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001856414-24-000004 · wk-form4_1708734159.xml · derivative · entry 4 Marriott Tina · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 496,000 Underlying: Class A Common Stock · 8,000 shares Expires 2028-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date. Read SEC document |
| February 22, 2024 Filed Feb 24, 2024 00:22 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 8,000 | $14.90 | $119,160.00 |
DisclosureSEC source: 0001856414-24-000004 · wk-form4_1708734159.xml · nonDerivative · entry 2 Marriott Tina · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 639,982 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $14.42 to $15.19. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 22, 2024 Filed Feb 24, 2024 00:22 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 8,000 | $1.06 | $8,480.00 |
DisclosureSEC source: 0001856414-24-000004 · wk-form4_1708734159.xml · nonDerivative · entry 1 Marriott Tina · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 647,982 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023. Read SEC document |
| February 15, 2024 Filed Feb 17, 2024 00:58 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 5,379 | $12.43 | $66,860.97 |
DisclosureSEC source: 0001209191-24-003487 · doc4.xml · nonDerivative · entry 1 Marriott Tina · CIK 0001856414 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 639,982 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| February 09, 2024 Filed Feb 14, 2024 00:00 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantStock Option (Right to Buy) · Derivative | 447,917 | $0.00 Strike: $10.09 | $0.00 |
DisclosureSEC source: 0001209191-24-003236 · doc4.xml · derivative · entry 9 Marriott Tina · CIK 0001856414 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 447,917 Underlying: Class A Common Stock · 447,917 shares Expires 2034-02-09 F8 · derivative.exercise_date: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. Read SEC document |
| February 09, 2024 Filed Feb 14, 2024 00:00 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 2,800 | $10.09 | $28,252.00 |
DisclosureSEC source: 0001209191-24-003236 · doc4.xml · nonDerivative · entry 3 Marriott Tina · CIK 0001856414 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 645,361 F3 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| February 09, 2024 Filed Feb 14, 2024 00:00 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 223,958 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-003236 · doc4.xml · nonDerivative · entry 2 Marriott Tina · CIK 0001856414 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 648,161 F2 · kind: This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on May 15, 2024 and every three months thereafter. Read SEC document |
| February 09, 2024 Filed Feb 14, 2024 00:00 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 9,655 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-003236 · doc4.xml · nonDerivative · entry 1 Marriott Tina · CIK 0001856414 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 424,203 F1 · kind: This RSU vested immediately upon the grant date. Read SEC document |
| January 25, 2024 Filed Jan 29, 2024 23:52 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001209191-24-002391 · doc4.xml · derivative · entry 4 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 504,000 Underlying: Class A Common Stock · 8,000 shares Expires 2028-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023. F4 · derivative.exercise_date: Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date. Read SEC document |
| January 25, 2024 Filed Jan 29, 2024 23:52 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 8,000 | $10.35 | $82,761.60 |
DisclosureSEC source: 0001209191-24-002391 · doc4.xml · nonDerivative · entry 2 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 414,548 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $10.17 to $10.54 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| January 25, 2024 Filed Jan 29, 2024 23:52 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 8,000 | $1.06 | $8,480.00 |
DisclosureSEC source: 0001209191-24-002391 · doc4.xml · nonDerivative · entry 1 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 422,584 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023. Read SEC document |
| December 28, 2023 Filed Jan 2, 2024 21:58 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001209191-24-000175 · doc4.xml · derivative · entry 4 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 512,000 Underlying: Class A Common Stock · 8,000 shares Expires 2028-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023. F5 · derivative.exercise_date: Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date. Read SEC document |
| December 28, 2023 Filed Jan 2, 2024 21:58 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 8,000 | $10.58 | $84,653.60 |
DisclosureSEC source: 0001209191-24-000175 · doc4.xml · nonDerivative · entry 2 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 414,548 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023. F3 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $10.34 to $10.75 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| December 28, 2023 Filed Jan 2, 2024 21:58 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 8,000 | $1.06 | $8,480.00 |
DisclosureSEC source: 0001209191-24-000175 · doc4.xml · nonDerivative · entry 1 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 422,548 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023. F2 · balance_after: Includes 1,144 shares purchased pursuant to the Issuer's Employee Stock Purchase Plan on November 20, 2023. Read SEC document |
| November 16, 2023 Filed Nov 17, 2023 22:53 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001209191-23-055846 · doc4.xml · derivative · entry 5 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 520,000 Underlying: Class A Common Stock · 3,000 shares Expires 2028-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023. F5 · derivative.exercise_date: Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date. Read SEC document |
| November 16, 2023 Filed Nov 17, 2023 22:53 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 3,000 | $6.76 | $20,279.70 |
DisclosureSEC source: 0001209191-23-055846 · doc4.xml · nonDerivative · entry 3 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 413,404 F2 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023. F3 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $6.61 to $7.18 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| November 16, 2023 Filed Nov 17, 2023 22:53 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 3,000 | $1.06 | $3,180.00 |
DisclosureSEC source: 0001209191-23-055846 · doc4.xml · nonDerivative · entry 2 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 416,404 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 22:53 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 5,378 | $7.18 | $38,614.04 |
DisclosureSEC source: 0001209191-23-055846 · doc4.xml · nonDerivative · entry 1 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 413,404 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| October 26, 2023 Filed Oct 30, 2023 22:26 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001209191-23-053890 · doc4.xml · derivative · entry 4 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 523,000 Underlying: Class A Common Stock · 3,000 shares Expires 2028-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023. F4 · derivative.exercise_date: Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date. Read SEC document |
| October 26, 2023 Filed Oct 30, 2023 22:26 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 3,000 | $5.63 | $16,884.90 |
DisclosureSEC source: 0001209191-23-053890 · doc4.xml · nonDerivative · entry 2 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 418,782 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $5.55 to $5.76 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| October 26, 2023 Filed Oct 30, 2023 22:26 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 3,000 | $1.06 | $3,180.00 |
DisclosureSEC source: 0001209191-23-053890 · doc4.xml · nonDerivative · entry 1 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 421,782 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023. Read SEC document |
| September 28, 2023 Filed Oct 2, 2023 22:19 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001209191-23-051191 · doc4.xml · derivative · entry 4 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 526,000 Underlying: Class A Common Stock · 3,000 shares Expires 2028-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023. F4 · derivative.exercise_date: Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.